Drug Metabolism and Pharmacokinetics Drug Metabolism and Pharmacokinetics RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition
In conclusion, B-01 ester compounds may be safe PK boosters with antedrug characteristics.PMID:38663182 | DOI:10.1016/j.dmpk.2024.101005 (Source: Drug Metabolism and Pharmacokinetics)
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Makoto Kataoka Sae Takenaka Shota Fujii Takato Masada Keiko Minami Toshihide Takagi Masaaki Omote Kentaro Kawai Shinji Yamashita Source Type: research

Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery
Drug Metab Pharmacokinet. 2024 Mar 11;56:101008. doi: 10.1016/j.dmpk.2024.101008. Online ahead of print.ABSTRACTWe aimed at predicting the drug-drug interaction (DDI) risk of P-glycoprotein (P-gp) substrates by using P-gp expressing LLC-PK1 cells and its knockout mice (KO). The area under the curve (AUC) of 16 marketed drugs and plasma concentration (Cplasma) of 207 screening compounds, with corrected efflux ratio (CER) ≥ 2, were compared between P-gp KO mice and wild type mice (WT). At permeability (Papp) ≥ 10 × 10-6 cm/s in parent LLC-PK1 cells, AUC ratios (KO/WT) and Cplasma ratios (KO/WT) of these compounds were w...
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Yasuto Kido Isamu Nanchi Takanobu Matsuzaki Ryosuke Watari Hayato Kiyohara Naomi Seki Tomohiko Okuda Source Type: research

In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition
In conclusion, B-01 ester compounds may be safe PK boosters with antedrug characteristics.PMID:38663182 | DOI:10.1016/j.dmpk.2024.101005 (Source: Drug Metabolism and Pharmacokinetics)
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Makoto Kataoka Sae Takenaka Shota Fujii Takato Masada Keiko Minami Toshihide Takagi Masaaki Omote Kentaro Kawai Shinji Yamashita Source Type: research

Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery
Drug Metab Pharmacokinet. 2024 Mar 11;56:101008. doi: 10.1016/j.dmpk.2024.101008. Online ahead of print.ABSTRACTWe aimed at predicting the drug-drug interaction (DDI) risk of P-glycoprotein (P-gp) substrates by using P-gp expressing LLC-PK1 cells and its knockout mice (KO). The area under the curve (AUC) of 16 marketed drugs and plasma concentration (Cplasma) of 207 screening compounds, with corrected efflux ratio (CER) ≥ 2, were compared between P-gp KO mice and wild type mice (WT). At permeability (Papp) ≥ 10 × 10-6 cm/s in parent LLC-PK1 cells, AUC ratios (KO/WT) and Cplasma ratios (KO/WT) of these compounds were w...
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Yasuto Kido Isamu Nanchi Takanobu Matsuzaki Ryosuke Watari Hayato Kiyohara Naomi Seki Tomohiko Okuda Source Type: research

In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition
In conclusion, B-01 ester compounds may be safe PK boosters with antedrug characteristics.PMID:38663182 | DOI:10.1016/j.dmpk.2024.101005 (Source: Drug Metabolism and Pharmacokinetics)
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Makoto Kataoka Sae Takenaka Shota Fujii Takato Masada Keiko Minami Toshihide Takagi Masaaki Omote Kentaro Kawai Shinji Yamashita Source Type: research

Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery
Drug Metab Pharmacokinet. 2024 Mar 11;56:101008. doi: 10.1016/j.dmpk.2024.101008. Online ahead of print.ABSTRACTWe aimed at predicting the drug-drug interaction (DDI) risk of P-glycoprotein (P-gp) substrates by using P-gp expressing LLC-PK1 cells and its knockout mice (KO). The area under the curve (AUC) of 16 marketed drugs and plasma concentration (Cplasma) of 207 screening compounds, with corrected efflux ratio (CER) ≥ 2, were compared between P-gp KO mice and wild type mice (WT). At permeability (Papp) ≥ 10 × 10-6 cm/s in parent LLC-PK1 cells, AUC ratios (KO/WT) and Cplasma ratios (KO/WT) of these compounds were w...
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Yasuto Kido Isamu Nanchi Takanobu Matsuzaki Ryosuke Watari Hayato Kiyohara Naomi Seki Tomohiko Okuda Source Type: research

In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition
In conclusion, B-01 ester compounds may be safe PK boosters with antedrug characteristics.PMID:38663182 | DOI:10.1016/j.dmpk.2024.101005 (Source: Drug Metabolism and Pharmacokinetics)
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Makoto Kataoka Sae Takenaka Shota Fujii Takato Masada Keiko Minami Toshihide Takagi Masaaki Omote Kentaro Kawai Shinji Yamashita Source Type: research

Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery
Drug Metab Pharmacokinet. 2024 Mar 11;56:101008. doi: 10.1016/j.dmpk.2024.101008. Online ahead of print.ABSTRACTWe aimed at predicting the drug-drug interaction (DDI) risk of P-glycoprotein (P-gp) substrates by using P-gp expressing LLC-PK1 cells and its knockout mice (KO). The area under the curve (AUC) of 16 marketed drugs and plasma concentration (Cplasma) of 207 screening compounds, with corrected efflux ratio (CER) ≥ 2, were compared between P-gp KO mice and wild type mice (WT). At permeability (Papp) ≥ 10 × 10-6 cm/s in parent LLC-PK1 cells, AUC ratios (KO/WT) and Cplasma ratios (KO/WT) of these compounds were w...
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Yasuto Kido Isamu Nanchi Takanobu Matsuzaki Ryosuke Watari Hayato Kiyohara Naomi Seki Tomohiko Okuda Source Type: research

In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition
In conclusion, B-01 ester compounds may be safe PK boosters with antedrug characteristics.PMID:38663182 | DOI:10.1016/j.dmpk.2024.101005 (Source: Drug Metabolism and Pharmacokinetics)
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Makoto Kataoka Sae Takenaka Shota Fujii Takato Masada Keiko Minami Toshihide Takagi Masaaki Omote Kentaro Kawai Shinji Yamashita Source Type: research

Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery
Drug Metab Pharmacokinet. 2024 Mar 11;56:101008. doi: 10.1016/j.dmpk.2024.101008. Online ahead of print.ABSTRACTWe aimed at predicting the drug-drug interaction (DDI) risk of P-glycoprotein (P-gp) substrates by using P-gp expressing LLC-PK1 cells and its knockout mice (KO). The area under the curve (AUC) of 16 marketed drugs and plasma concentration (Cplasma) of 207 screening compounds, with corrected efflux ratio (CER) ≥ 2, were compared between P-gp KO mice and wild type mice (WT). At permeability (Papp) ≥ 10 × 10-6 cm/s in parent LLC-PK1 cells, AUC ratios (KO/WT) and Cplasma ratios (KO/WT) of these compounds were w...
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Yasuto Kido Isamu Nanchi Takanobu Matsuzaki Ryosuke Watari Hayato Kiyohara Naomi Seki Tomohiko Okuda Source Type: research

In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition
In conclusion, B-01 ester compounds may be safe PK boosters with antedrug characteristics.PMID:38663182 | DOI:10.1016/j.dmpk.2024.101005 (Source: Drug Metabolism and Pharmacokinetics)
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Makoto Kataoka Sae Takenaka Shota Fujii Takato Masada Keiko Minami Toshihide Takagi Masaaki Omote Kentaro Kawai Shinji Yamashita Source Type: research

Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery
Drug Metab Pharmacokinet. 2024 Mar 11;56:101008. doi: 10.1016/j.dmpk.2024.101008. Online ahead of print.ABSTRACTWe aimed at predicting the drug-drug interaction (DDI) risk of P-glycoprotein (P-gp) substrates by using P-gp expressing LLC-PK1 cells and its knockout mice (KO). The area under the curve (AUC) of 16 marketed drugs and plasma concentration (Cplasma) of 207 screening compounds, with corrected efflux ratio (CER) ≥ 2, were compared between P-gp KO mice and wild type mice (WT). At permeability (Papp) ≥ 10 × 10-6 cm/s in parent LLC-PK1 cells, AUC ratios (KO/WT) and Cplasma ratios (KO/WT) of these compounds were w...
Source: Drug Metabolism and Pharmacokinetics - April 25, 2024 Category: Drugs & Pharmacology Authors: Yasuto Kido Isamu Nanchi Takanobu Matsuzaki Ryosuke Watari Hayato Kiyohara Naomi Seki Tomohiko Okuda Source Type: research

Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action
Drug Metab Pharmacokinet. 2024 Jan 23;56:101001. doi: 10.1016/j.dmpk.2024.101001. Online ahead of print.ABSTRACTTrastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate used for cancer treatment comprising an anti-human epidermal growth factor receptor type 2 (HER2) antibody and the topoisomerase I inhibitor DXd. The present study investigated the intratumor fate of T-DXd. Fluorescence-labeled T-DXd was found to accumulate in tumors of HER2-positive tumor xenograft mice and was observed to be distributed within lysosomes of in vitro tumor cells in accordance with their HER2 expression. DXd was released by cysteine prot...
Source: Drug Metabolism and Pharmacokinetics - April 21, 2024 Category: Drugs & Pharmacology Authors: Yoko Nagai Masataka Oitate Takahiro Shibayama Hideo Takakusa Nobuaki Watanabe Source Type: research